AIFF
Firefly Neuroscience, Inc. Common StockAIFF
AIFF
About: Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders.
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
52% more capital invested
Capital invested by funds: $393K [Q3] → $597K (+$204K) [Q4]
22% more funds holding
Funds holding: 9 [Q3] → 11 (+2) [Q4]
0.89% more ownership
Funds ownership: 1.76% [Q3] → 2.65% (+0.89%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for AIFF.
Financial journalist opinion
Based on 3 articles about AIFF published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
Extends cash runway well into mid-2026; no new/replacement warrants issued Extends cash runway well into mid-2026; no new/replacement warrants issued
Neutral
GlobeNewsWire
1 week ago
Firefly Neuroscience Accepted into NVIDIA Connect Program
Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform
Neutral
GlobeNewsWire
2 weeks ago
Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics
- University of Waterloo's Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award - - Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay the groundwork for an exciting new brain model initiative to be revealed soon - KENMORE, N.Y., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to congratulate Christopher Wilson, PhD, on being recognized by the University of Waterloo's (“UW”) Faculty of Engineering for his significant contributions to research and scholarship.
Positive
Benzinga
1 month ago
Crude Oil Down 1%; Firefly Neuroscience Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday.
Neutral
GlobeNewsWire
1 month ago
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients
Neutral
GlobeNewsWire
1 month ago
Firefly Neuroscience Closes on Financing of up to $12.4 Million
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the closing of up to $12.4 million consisting of $2.4 million up front in the form of senior secured convertible notes at $3.00 per share, subject to adjustment, and an equity line of credit (the “ELOC”) for up to $10 million. The proceeds from these financings will be used for growth, commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) technology, and general working capital purposes.
Neutral
GlobeNewsWire
3 months ago
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering with brain health illnesses by bringing objective measurement of brain activity to the front lines of healthcare.
Neutral
GlobeNewsWire
3 months ago
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the Capital Event Management Conference being held at the JW Marriott Miami in Aventura, Florida on November 22-24, 2024.
Neutral
GlobeNewsWire
3 months ago
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that the Board of Directors of Firefly granted 557,885 restricted shares (the “Shares”) as an inducement grant to David Johnson, the Company's Executive Chairman, pursuant to that certain Employment Agreement (the “Agreement”), by and between the Company and Mr. Johnson. The Shares were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the Agreement and the Company's 2024 Long-Term Incentive Plan.
Neutral
GlobeNewsWire
4 months ago
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly's advanced AI BNA technology analysis platform During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly's advanced AI BNA technology analysis platform
Charts implemented using Lightweight Charts™